Familial hypercholesterolemia review of diagnosis, screening, and treatment

Canadian Family Physician

Volumn 62, Issue 1, 2016, Pages

  Turgeon, Ricky D ^a   Barry, Arden R ^b   Pearson, Glen J ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SCREENING; SIDE EFFECT; SYSTEMATIC REVIEW; BLOOD; CANADA; CARDIOVASCULAR DISEASES; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; PROCEDURES;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING;

EID: 84955581609     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, Couture P, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014;30(12):1471-81. Epub 2014 Oct 2.
2. World Health Organization. Familial hypercholesterolaemia (FH). Report of a second WHO consultation. Geneva, Switz: World Health Organization; 1999. Available from: http://apps.who.int/iris/bitstream/10665/66346/1/ WHO-HGN-FH-CONS-99.2.pdf. Accessed 2015 Nov 23.
3. Faiz F, Hooper AJ, van Bockxmeer FM. Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. Crit Rev Clin Lab Sci 2012;49(1):1-17. Epub 2012 Jan 4.
4. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35(32):2146-57. Epub 2014 Jul 22.
5. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160(5):407-20.
6. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49(3):476-88.
7. Hu M, Lan W, Lam CW, Mak YT, Pang CP, Tomlinson B. Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int J Cardiol 2013;167(3):762-7. Epub 2012 Mar 30.
8. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29(2):151-67.
9. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124(20):2202-7. Epub 2011 Oct 10.
10. Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet 2012;379(9823):1330. Epub 2012 Jan 27.
11. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213-56. Epub 2011 Nov 14.
12. Newman TB, Pletcher MJ, Hulley SB. Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics 2012;130(2):349-52. Epub 2012 Jul 23.
13. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357(9251):165-8.
14. Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013;167(6):2391-6. Epub 2013 Mar 13.
15. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5(Suppl 3):S9-17. Epub 2011 Apr 3.
16. Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol 2014;7(2):107-17.
17. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102(9):1187-93, 1193.e1. Epub 2008 Aug 27.
18. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97(11):3956-64. Epub 2012 Aug 14.
19. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
20. National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care. Identification and management of familial hypercholesterolaemia. NICE clinical guidelines, no. 71. London, UK: Royal College of General Practitioners; 2008.
21. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171(3):309-25. Epub 2013 Nov 20.
22. Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014;(6):CD001918.
23. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256(6):482-90.
24. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357(9256):577-81.
25. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35. Epub 2005 Mar 8.
26. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142(1):105-12.
27. Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010;17(7):667-74. Epub 2010 Jun 4.
28. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431-43. Epub 2008 Mar 30.
29. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372(25):2387-97. Epub 2015 Jun 3.
30. Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother 2011;45(10):1230-9. Epub 2011 Sep 13.
31. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371(3):203-12.
32. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014;129(9):1022-32.
33. Aegerion Pharmaceuticals. Juxtapid [product monograph]. Toronto, ON: Aegerion Pharmaceuticals; 2014. Available from: www.aegerion.ca/ collateral/documents/Canada-English/FINAL%20Pristine%20 Monograph%20copy.pdf. Accessed 2015 Nov 23.
34. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381(9860):40-6. Epub 2012 Nov 2.
35. Genzyme [website]. Kynamaro. Highlights of prescribing information. Cambridge, MA: Genzyme; 2013. Available from: www.genzyme.com/ Products/~/media/B866EE59A7C14916BFBFB4ECAA1C7087.pdf. Accessed 2015 Nov 23.
36. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006.
37. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-9. Epub 2010 Mar 30.
38. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163(1):40-51.
39. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010;(7):CD006401.
40. Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55(11):1121-6.
41. Van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52(17):1421-9.